

Gregory J. Hindy Partner T. 973-639-6954 F. 973-297-3883 ghindy@mccarter.com

McCarter & English, LLP Four Gateway Center 100 Mulberry Street Newark, NJ 07102-4056 www.mccarter.com

October 18, 2021

VIA ECF

William T. Walsh, Clerk of Court United States District Court – District of New Jersey Martin Luther King Building & U.S. Courthouse 50 Walnut Street Newark, N.J. 07102

Re: Proton-Pump Inhibitor Products Liability Litigation (No. II) 2:17-md-2789 (CCC)(MF) (MDL 2789) This Document Relates to: Bales v. AstraZeneca Pharmaceuticals LP, No. 2:17-cv-06124 [ECF No. 81] Foster v. AstraZeneca Pharmaceuticals LP, No. 2:17-cv-02475 [ECF No. 66] Lee v. AstraZeneca Pharmaceuticals LP, No. 2:17-cv-00212 [ECF No. 59] Nelson v. AstraZeneca Pharmaceuticals LP, No. 2:17-cv-13727 [ECF No. 35] Kersch v. AstraZeneca LP, No. 2:18-cv-03159 [ECF No. 52] Rieder v. AstraZeneca Pharmaceuticals LP, No. 2:19-cv-00850 [ECF No. <u>37</u>]

This firm represents Defendants AstraZeneca Pharmaceuticals LP, AstraZeneca LP, and Merck Sharp & Dohme Corporation ("Defendants"). On October 15, 2021, Defendants filed a Motion to Exclude Opinion Testimony from Plaintiffs' General Causation Experts under Federal Rule of Evidence 702 in the above-referenced matters and document numbers containing confidential information. During electronic filing, the CM/ECF system did not permit Defendants to file the motions under temporary Accordingly, Defendants respectfully request the Clerk's Office place the following filings under temporary seal pending Defendants' forthcoming Motion to Seal pursuant to Local Civil Rule 5.3.

We thank the Court for its attention to this matter.

Respectfully submitted, /s/ Gregory J. Hindy Gregory J. Hindy

Page 2

MCCARTER & ENGLISH, LLP

Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07101-0652
(973) 622-4444
ghindy@mccarter.com
Attorneys for AstraZeneca
Pharmaceuticals LP, AstraZeneca LP,
and Merck Sharp & Dohme Corporation